Egrifta (Tesamorelin Injection) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 27, 2012

Egrifta

Human Immunodeficiency Virus »

HIV facts

The human immunodeficiency virus (HIV) is a type of virus called a retrovirus, which infects humans when it comes in contact with tissues such as those that line the vagina, anal area, mouth, or eyes, or through a break in the skin.
HIV infection is generally a slowly progressive disease in which the virus is present throughout the body at all stages of the disease.
Three stages of HIV infection have been described.

The initial stage of infection (primary infection), which occurs within weeks of acquiring the virus, and often is characterized by a flu- or mono-like illness that generally resolves within weeks.
The stage of chronic asymptomatic infection (meaning a long duration of infection without symptoms) lasts an average of eight to 10 years.
The stage of symptomatic infection, in which the body's immune (or defense) system has...

Read the Human Immunodeficiency Virus article »

« Previous
1
2
3
4
5
6
7
8
9
10
Next »

Egrifta User Reviews >>

Egrifta

HIV AIDS Myths and Facts Slideshow Pictures

Take the HIV/AIDS Quiz

AIDS Retrospective Slideshow Pictures

font size

EGRIFTA™
(tesamorelin) for Injection, for subcutaneous use.

DRUG DESCRIPTION

EGRIFTA™ contains tesamorelin (as the acetate salt), an analog of human growth hormone-releasing factor (GRF). The peptide precursor of tesamorelin acetate is produced synthetically and is comprised of the 44 amino acid sequence of human GRF. Tesamorelin acetate is made by attaching a hexenoyl moiety, a C6 chain with a double bond at position 3, to the tyrosine residue at the N-terminal part of the molecule. The molecular formula of tesamorelin acetate is C₂₂₁H₃₆₆N₇₂O₆₇S • x C₂H₄O₂ (x ≈7) and its molecular weight (free base) is 5135.9 Daltons. The structural formula of tesamorelin acetate is:

EGRIFTA™
(tesamorelin acetate) Structural Formula Illustration

EGRIFTA™ is a sterile, white to off-white, preservative-free lyophilized powder for subcutaneous injection. After reconstitution with the supplied diluent (Sterile Water for Injection, USP), a solution of EGRIFTA™ is clear and colorless. Each single-use vial of EGRIFTA™ contains 2 mg of tesamorelin as the free base (2.2 mg tesamorelin acetate, anhydrous) and the following inactive ingredient: 100 mg mannitol, USP.

What are the precautions when taking tesamorelin injection (Egrifta)?

Before using this medication, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.

Before using this medication, tell your doctor or pharmacist your medical history, especially of: cancer, diabetes, tumors, hypothalamus or pituitary gland problems (such as due to head injury, pituitary tumor/surgery).

Before having surgery, tell your doctor or dentist about all the products you use (including prescription drugs, nonprescription drugs, and herbal products).

This medication must not be used during pregnancy. It may harm an unborn baby. If you become pregnant or think you may be pregnant,...

Read All Potential Precautions of Egrifta »

Last reviewed on RxList: 12/12/2011
This monograph has been modified to include the generic and brand name in many instances.